Toronto Dominion Bank Cybin Inc. Transaction History

Toronto Dominion Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.38 - $0.65 $171 - $293	451 Added 33.88%	1,782 $0
Q2 2023 Feb 14, 2024	SELL	$0.23 - $0.39 $103 - $175	-451 Reduced 25.31%	1,331 $0
Q1 2023 May 11, 2023	SELL	$0.3 - $0.56 $800 - $1,494	-2,669 Reduced 66.73%	1,331 $1,000
Q4 2022 Feb 07, 2023	BUY	$0.26 - $0.47 $650 - $1,175	2,500 Added 166.67%	4,000 $1,000
Q3 2022 Nov 09, 2022	SELL	$0.54 - $1.11 $2,182 - $4,486	-4,042 Reduced 72.93%	1,500 $1,000

Q2 2022 Aug 11, 2022	SELL	$0.41 - $0.88 $615 - $1,320	-1,500 Reduced 21.3%	5,542 $3,000
Q1 2022 May 09, 2022	BUY	$0.74 - $1.22 $5,180 - $8,540	7,000 Added 16666.67%	7,042 $6,000
Q3 2021 Nov 08, 2021	BUY	$1.83 - $3.18 $76 - $133	42 New	42 $0

109

243M

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $43.2M
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Toronto Dominion Bank, based on Form 13F filings with the SEC.

Stay updated on Toronto Dominion Bank with notifications on news.